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Abstract 
Background: Artesunate‑amodiaquine (AS‑AQ) and artemether‑lumefantrine (AL) are first‑ and second‑line treat‑
ments for uncomplicated Plasmodium falciparum malaria in Gabon. AL remains highly efficacious, but its widespread 
use has led to molecular selection of the NFD haplotype on Pfmdr1 and K76 in Pfcrt. In this study, plasmodial infection 
characteristics and the distribution of the Pfmdr1 and Pfcrt genotypes involved in reduced efficacy of artemisinin‑
based combination therapy (ACT) were investigated in four Gabonese localities.
Methods: A cross‑sectional study was conducted in the paediatric units of rural (Lastourville and Fougamou), semi‑
urban (Koula‑Moutou) and urban (Franceville) areas. Malaria was diagnosed with the rapid diagnostic test Optimal‑IT® 
and confirmed by blood smear. Pfmdr1 codons 86, 184 and 1246 and Pfcrt codon 76 were genotyped by PCR–RFLP 
and sequencing.
Results: Among 1129 included children, the prevalence of plasmodial infection was 79.5 % at Lastourville, 53.6 % 
at Fougamou, 36.1 % at Koula‑Moutou, and 21.2 % at Franceville. The prevalence was significantly higher among 
children over 60 months of age in both semi‑urban (p = 0.01) and urban (p = 0.004) areas. The prevalence of Pfmdr1 
wild‑type N86 differed significantly between Lastourville (57.8 %) and Koula‑Moutou (45.4 %) (p = 0.039). No dif‑
ference in 184F‑carrying parasites was found between Lastourville (73.8 %), Fougamou (81.6 %), Koula‑Moutou 
(83.2 %), and Franceville (80.6 %) (p = 0.240). The prevalence of wild‑type D1246 was significantly different between 
Lastourville (94.1 %), Koula‑Moutou (85.6 %) and Franceville (87.3 %) (p = 0.01). The frequency of wild‑type K76 was 
not significantly different across the four sites: Lastourville (16.5 %), Fougamou (27.8 %), Koula‑Moutou (17.4 %), and 
Franceville (29.4 %) (p = 0.09). The mixed genotypes were only found in Lastourville and Franceville. The NFD, YFD 
and NYD haplotypes were mainly Lastourville (46.6, 25.8, 14.0 %), Fougamou (45.5, 9.1, 42.4 %), Koula‑Moutou (35, 6.7, 
40.4 %), and Franceville (40.0, 16.0, 32.0 %).
Conclusion: This study shows an increase in the prevalence of childhood plasmodial infection in Gabon according to 
the low socio‑economic level, and a high frequency of markers associated with AL treatment failure. Close monitoring 
of ACT use is needed.
Keywords: Pfmdr1, Pfcrt, Haplotype, ACT, Resistance, SNPs, Children, Gabon
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  Lekana_jb@yahoo.fr 
4 Département de Parasitologie‑Mycologie Médecine Tropicale, Faculté 
de Médecine, Université des Sciences de la Santé, B.P. 4009,  
Libreville, Gabon
Full list of author information is available at the end of the article
Page 2 of 9Maghendji‑Nzondo et al. Malar J  (2016) 15:420 
Background
Plasmodium falciparum malaria is the most frequent 
parasitic infection worldwide, and is especially preva-
lent in sub-Saharan Africa. Anti-malarial drugs, such as 
chloroquine (CQ), amodiaquine (AQ) and sulfadoxine-
pyrimethamine (SP) have lost some of their efficacy in 
malaria-endemic countries [1, 2]. The World Health 
Organization (WHO) has recommended the use of arte-
misinin-based combination therapy (ACT) to limit the 
drug resistance emergence since 2000. Cases of parasite 
resistance to artemisinin have now been detected in four 
countries of the Greater Mekong Sub-region: Cambodia, 
Myanmar, Thailand, and Viet Nam [3–5].
ACT treatment failures are linked to the selection of 
certain parasitic genotypic variants such as Pfmdr1 N86 
and Pfcrt K76 [6–8]. The Pfmdr1 gene has been linked 
to resistance to CQ, AQ and mefloquine (MQ). Single 
nucleotide polymorphisms (SNPs) at codons 86 (N86Y), 
184 (Y184F) and 1246 (D1246Y) confer reduced parasite 
sensitivity to various drugs, including ACT [6, 9–11]. For 
example, the Pfmdr-1 Y86 mutation is associated with 
high-level CQ resistance when combined with the Plas-
modium falciparum CQ resistance transporter (Pfcrt) 
T76 genotype [12, 13].
It has recently been shown that certain combinations of 
SNPs in the Pfmdr-1 gene, at codons 86, 184 and 1246, 
are emerging in areas where the ACT drug combination 
artemether-lumefantrine (AL) is widely used [14]. Cer-
tain Pfmdr-1 haplotypes may be markers of emerging 
ACT tolerance [15]. Recent studies have shown that a 
combination of N86, 184F and D1246, creating the ‘NFD’ 
haplotype, reduces parasite susceptibility to AL, and that 
treatment with AL selects this haplotype [16, 17]. Other 
studies have shown that the combination of Pfmdr-1 YYY 
haplotypes at codons 86/184/1246 are selected by AQ 
monotherapy and increase the risk of AQ failure [9, 10]. 
SNPs at positions 1034 and 1042 of pfmdr1 have been 
shown to alter the drug-binding pocket in Pfmdr1 [18] 
and are frequently found in Africa.
Gabon, in Equatorial Africa, is located in a hyper-
endemic area where malaria transmission is peren-
nial. Resistance to CQ, AQ and sulfadoxine has already 
been described [19–21]. The 2003 consensus meeting in 
Gabon adopted ACT for the treatment of uncomplicated 
malaria and called for the withdrawal of CQ and other 
monotherapy. Artesunate-amodiaquine (AS-AQ) and 
AL were adopted as first- and second-line treatment for 
uncomplicated P. falciparum malaria, and quinine (QN) 
for severe malaria [22]. This led to a significant reduction 
in the paediatric malaria burden, in urban areas [23, 24]. 
ACT is currently implemented in urban and rural areas 
in Gabon, but few data on the prevalence of molecu-
lar markers of tolerance are available. Data from several 
rural areas are not available. Nothing is known of the use 
of preventative measures.
Franceville is a city with high levels of P. falciparum 
drug resistance, and in vitro reduced dihydroartemisinin 
(DHA) sensitivity has been reported [25]. It has recently 
been shown that the use of ACT selected the N86 geno-
type in Franceville [26]. This genotype is now suspected 
of being a marker of parasite tolerance of ACT [6, 11]. 
The purpose of the present study was to determine the 
general childhood malaria prevalence and to character-
ize the distribution of molecular genotypes of the Pfmdr1 
and Pfcrt genes involved in reduced P. falciparum clear-
ance by ACT in four Gabonese localities.
Methods
Sites and study population
This study took place between May 2013 and July 2014 
in four localities of southeast Gabon (Fig.  1): Fouga-
mou, a rural area of Ngounie province; Lastourville and 
Koula-Moutou, rural and semi-urban areas of Ogooue-
Lolo province; Franceville, the provincial capital of 
Haut-Ogooue. Blood samples were taken during out-
patient paediatric consultations at the health centres of 
Fougamou and Lastourville, and the regional hospitals 
Paul Moukambi and Amissa Bongo in Koula-Moutou 
and Franceville, after obtaining informed consent from 
parents/guardians. The study population consisted of 
febrile children (≥37.5  °C or a history of fever less than 
24 h before the consultation) aged from 6 to 168 months 
(15 years) in the outpatients’ departments of paediatrics. 
This age group was the most affected of the population by 
malaria. Children who did not fill the criteria and those 
Fig. 1 Map of Gabon. Study sites are underlined
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among whom informed consent of parents or guard-
ians was not obtained were excluded from the study. The 
study was approved by the Gabonese National Ethics 
Committee (no. 0023/2013/SG/CNE).
Malaria diagnosis
The Optimal-IT® rapid diagnostic test was used [27], and 
the sensibility and specificity test was 94 and 97 %. Pre-
ceding work in Gabon has shown that this test is a good 
tool for diagnosis of malaria [28]. Parasite load was deter-
mined on blood smears using the Lambarene method 
[29]. All blood smears were read by two independent 
technicians and quality control was done in 10 % of slides 
by a third reader. Fever and P. falciparum infection (1000 
parasites per µl of blood) was considered to be malaria.
Blood analysis
Routine haematological assays assessing the impact of 
malaria were done with an automated blood cell counter 
(STKS®, Coulter Corp, USA). Blood (5 ml) was collected 
in EDTA tubes. Plasma was stored at −20 °C and blood 
pellets were used for DNA extraction. Moderate anaemia 
was defined as a haemoglobin level between 5 and 10 g/
dl, and severe anaemia as a haemoglobin level ≤5 g/dl.
DNA extraction
DNA was extracted with the Omega Bio-Tek E.Z.N.A.1 
method (Omega Bio-Tek, USA) according to the manu-
facturer’s protocol [26]. Briefly, 250 µl of blood, 25 µl of 
Omega Biotek (OB) protease (20  mg/ml), and 250  µl of 
lysis buffer were mixed and heated to 65  °C for 30  min 
before adding 260  µl of isopropanol. The mixture was 
transferred to a column and centrifuged at 10,000  rpm 
for 1 min. The column was washed twice at 13,000 rpm 
for 2 min, and DNA was eluted with 90 µL of sterile water 
preheated to 65  °C. DNA samples were kept at −20  °C 
until use.
Amplification and genotyping of Pfmdr1 at codons 86, 184 
and 1246, and Pfcrt K76
Codons 86, 184, 1246, and 76 were amplified by nested 
PCR, using the primers listed in Extended Data [26, 30]. 
Five microlitre of DNA was amplified with 1X buffer, 
0.8  µM each primer, 0.2  mM dNTP (Invitrogen®), 
1.5 mM MgCl2 and 0.024 units of Taq DNA polymerase 
(Invitrogen®) using the following cycling programme: 
5  min at 94  °C, then 35 cycles of 30  s at 94  °C, 45  s at 
45 °C, 45 s at 72 °C, and a final extension step of 7 min at 
72  °C. Codons 86, 184, 1246, and 76 of the Pfmdr1 and 
Pfcrt genes were genotyped with a PCR–RFLP method 
as previously described [31]. The PCR products were 
digested with the restriction enzymes AflIII, DraI, BglII 
and ApoI (New England Biolabs, UK) for SNPs N86Y, 
Y184F, D1246Y and K76T, respectively. To confirm the 
genotypes, double-strand sequencing of PCR products 
was performed with the Macrogen® method. Sequences 
were analysed with MEGA6 software version 5.10 to 
identify specific SNP combinations. PCR products were 
detected by 2 % agarose gel electrophoresis.
Statistical analysis
Epi-info version 3.3.2 (2005, CDC, Atlanta, USA) and 
STATA version 14.0 (Stata Corp, College Station, USA) 
were used for statistical analyses. Age was expressed 
as the mean and standard deviation (SD), and parasite 
density as the geometric mean (GMPD) and range. The 
Chi square test was used to compare categorical vari-
ables, and the non-parametric Kruskal–Wallis test, Pear-
son’s test or Fisher’s exact test for group comparisons, as 




A total of 1129 children were included between May 2013 
and July 2014. The general characteristics of the children 
are described in Table 1. The proportion of children aged 
between 6 and 60 months was significantly different from 
the proportion of children older than 60  months at all 
the sites (p < 0.001). Mean age was higher in the urban 
and semi-urban areas than in the rural area (p < 0.001). 
Haematological parameters [haemoglobin, white blood 
cells, red blood cells (Hb, WBC, RBC)] differed signifi-
cantly between the rural (Lastourville) and urban areas 
(Franceville) (p  <  0.01). Platelet counts differed signifi-
cantly between the rural, semi-urban and urban areas 
(p < 0.001).
Plasmodium characterization
The prevalence of Plasmodium infection was, respec-
tively, 79.5, 53.6, 36.1, and 21.2  % at Lastourville, Foug-
amou, Koula-Moutou, and Franceville. The overall 
prevalence was higher in rural areas (74.2 %; n = 351/473) 
than in semi-urban and urban areas (p < 0.001).
As shown in Table  2, Plasmodium-infected children 
were older than uninfected children at Lastourville, 
Koula-Moutou and Franceville. The Kruskal–Wallis test 
showed a significant difference (p  <  0.001) in mean age 
between the rural, semi-urban and urban areas.
Haemoglobin, red blood cell, white blood cell, and 
platelet values were lower in Plasmodium-infected chil-
dren than in uninfected children (p < 0.001) in the semi-
urban area (Koula-Moutou). The Kruskal–Wallis test 
showed a significant difference in mean haematological 
values (Hb, WBC, RBC, platelets) between rural, semi-
urban and urban areas (p < 0.001).
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Finally, a significant difference in mean parasitae-
mia was observed between Lastourville and Koula-
Moutou (p < 0.001), between Lastourville and Fougamou 
(p =  0.011), Koula-Moutou and Fougamou (p  <  0.001), 
between Koula-Moutou and Franceville (p  =  0.006), 
and between Franceville and Fougamou (p  =  0.006). 
The prevalence of plasmodial infection is summarized in 
Table 1 according to the age group (<60 and >60 months).
Preventive measures
Univariate and multivariate analysis showed no associa-
tion between the use of preventive measures and malaria 
prevalence, excepted at Lastourville, where the use of bed 
nets was associated with a lower prevalence [p  <  0.001; 
OR 0.37 (0.22–0.64)] (Table 1).
Seasonality
In Gabon the year begins with a short dry season between 
January and February, then a long rainy season between 
March and May, followed by a long dry season between 
June and September, and finally a short rainy season 
between October and December. Figure 2 shows variations 
of malaria transmission during the period of study. Data 
showed that the frequency of plasmodial infection was sig-
nificantly different across the seasons at all sites (p < 0.001).
Prevalence of SNPs at codons 86, 184, 1246 of pfmdr1 
and codon 76 of Pfcrt
The distribution of SNPs at codons 86, 184, 1246 of 
Pfmdr1 and codon 76 of Pfcrt is summarized in Table 3 
for each locality.
The prevalence of wild-type N86 Pfmdr1 was sig-
nificantly different between Lastourville and Koula-
Moutou (p  =  0.03). The frequency of wild-type and 
mixed genotypes combined (N86 +  86  N/Y) was similar 
at all four sites (p  =  0.22). No difference in the propor-
tion of 184F-carrying parasites was found (p = 0.24). The 
prevalence of wild-type D1246 was significantly different 
between Lastourville and Koula-Moutou (p =  0.01). The 
frequency of wild-type and mixed genotypes combined 
(D1246  +  1246D/Y) was: Lastourville (97.4  %), Koula-
Moutou (98.2  %), Franceville (96.4  %). Mixed-genotype 
D1246/Y1246 infections were infrequent with a signifi-
cant difference between Lastourville and Koula-Moutou 
(p = 0.001).
Concerning the Pfcrt gene, the frequency of wild-type 
K76 was not significantly different across the four sites 
(p  =  0.09). The frequency of mixed genotypes 76KT 
was not significantly different between Lastourville and 
Franceville (p  =  0.244). The proportion of the mutated 
genotype (T76) was significantly different across the 
Table 1 Sociodemographic and biological characteristics of the included children by sites
IEK information, education and knowledge; LTV Lastourville; KMT Koula‑Moutou, FGM Fougamou, FCV Franceville; ND undetermined
a White blood cell
b Red blood cell
LTV p FGM p KMT p FCV p
(N = 387) (N = 98) (N = 357) (N = 280)
General characteristics
 Sex ratio 1.2 1.2 0.9 1.1
 Mean temperature ± SD (°C) 38.4 ± 1.2 38.4 ± 1.1 37.8 ± 1.3 38.3 ± 1 0.0001
 Mean age ± SD (month) 47.3 ± 34.7 44.03 ± 39.1 53.7 ± 49.1 59.4 ± 37.5 0.0001
 Haemoglobin (g/dl) 9.4 ± 2.2 ND 9.7 ± 1.9 10 ± 1.7 0.0001
 WBC (×103/µl)a 10.3 ± 6.3 ND 9.4 ± 3.9 8.9 ± 6.2 0.0009
 RBC (×106/µl)b 3.5 ± 0.9 ND 4.0 ± 0.8 4.5 ± 2.7 0.0001
 Platelet (×103/µl) 144.1 ± 121.6 ND 239.6 ± 134.9 255.3 ± 131.2 0.0001
Age group Prevalence of malaria infection [%; (n/N)]
<60 months 77.6 (211/272) 50.7 (36/71) 31.6 (72/228) 15.1 (23/152)
>60 months 84.2 (80/95) 58.3 (24/24) 46.1 (53/115) 28.7 (31/108)
p 0.2 0.68 0.01 0.004
Prevention measures Number of children (%, n)
Uninfected Infected p Uninfected Infected p Uninfected Infected p Uninfected Infected p
Bed net 66.7 (48) 42.7 (126) 0.004 71.1 (32) 79.2 (42) 0.48 66.2 (147) 64.6 (82) 0.84 53.3 (113) 48.2 (27) 0.59
Insecticides 13.9 (10) 14.1 (40) 0.88 21.9 (9) 18.9 (10) 0.91 30.2 (67) 27.8 (35) 0.72 39.3 (83) 33.9 (19) 0.55
Received an IEK on 
malaria
28.6 (20) 23.7 (67) 0.02 95.2 (40) 92.2 (47) 0.85 73.2 (161) 74.0 (91) 0.97 65.4 (138) 61.8 (34) 0.73
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four sites (p =  0.001). The difference was more marked 
between Lastourville (73.0  %) and Fougamou (72.2  %) 
(p = 0.009) and between Fougamou and Koula-Moutou 
(82.6  %) (p =  0.001). The difference was no longer sig-
nificant (p = 0.100) when the mixed genotype (KT) was 
included [Lastourville (83.5  %), Fougamou (72.2  %), 
Koula-Moutou (82.6  %), Franceville (70.6  %)]. The 
proportions of mixed genotypes did not differ between 
Lastourville and Franceville (p = 0.467).
Haplotype distribution
The haplotypes were compared on a three-codon basis at 
each site, and mixed-genotype infections were included 
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Fig. 2 Temporal distribution of plasmodial infection. Short rainy season (short blue line), long rainy season (large blue line), short dry season (short 
yellow line), and long dry season (large yellow line)
Table 3 Molecular markers and haplotype prevalence
ND p undetermined; LTV Lastourville; FGM Fougamou; KMT Koula‑Moutou; FCV Franceville
Prevalence by sites [%; (n/N)]
Genes Codons Genotypes LTV FGM KMT FCV p
Pfcrt
 SNPs 76 K 16.5 (33/200) 27.8 (10/36) 17.4 (20/115) 29.4 (15/51) 0.09
K/T 10.5 (21/200) 0.0 (0/36) 0.0 (0/115) 17.6 (9/51) ND
86 N 57.8 (144/249) 51.2 (21/41) 45.4 (49/108) 62.2 (23/37) 0.12
N/Y 10.4 (26/249) 17.1 (7/41) 17.6 (19/108) 5.4 (2/37) 0.10
184 Y/F 0.0 0.0 0.0 0.0 ND
F 73.8 (175/237) 81.6 (31/38) 83.2 (84/101) 80.6 (25/31) 0.24
1246 D 94.1 (255/271) 100.0 (32/32) 85.6 (95/111) 87.3 (48/55) ND
D/Y 3.3 (9/271) 0.0 (0/32) 12.6 (14/111) 9.1 (5/55) ND
pfmdr1
 Haplotypes 86/184/1246 NFD 46.6 (110/236) 45.5 (15/33) 35.0 (31/89) 40.0 (10/25) 0.28
NYD 14.0 (33/236) 9.1 (3/33) 6.7 (6/89) 16.0 (4/25) ND
YFD 25.8 (61/236) 42.4 (14/33) 40.4 (36/89) 32.0 (8/25) 0.03
YYD 8.5 (20/236) 3.0 (1/33) 4.5 (4/89) 4.0 (1/25) ND
NFY 1.3 (3/236) 0.0 6.7 (6/89) 0.0 ND
NYY 0.0 0.0 4.5 (4/89) 4.0 (1/25) ND
YYY 1.7 (4/236) 0.0 2.2 (2/89) 0.0 ND
YFY 2.1 (5/236) 0.0 0.0 4.0 (1/25) ND
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YFD were most prevalent at Lastourville and haplo-
types NFD and NYD were most prevalent at Fougamou, 
Koula-Moutou and Franceville. The prevalence of haplo-
type YFD was significantly different across the four sites: 
(p  =  0.03). This difference was most marked between 
Lastourville and Koula-Moutou (p = 0.02). Minor haplo-
types included YYD, NYY, YYY, NFY, and YFY.
Discussion
This study shows that the prevalence of malaria in Gabon 
differs significantly according to local economic status, 
confirming previous data [32]. Malaria prevalence has 
remained stable in Franceville since 2011 [24]. This study 
confirmed that transmission is perennial in Gabon. In 
rural areas, anti-malarial drugs are under-used despite 
the availability of ACT. Poor socio-economic conditions 
and inadequate knowledge of malaria could contribute to 
the high prevalence of malaria in rural areas. Indeed, the 
study revealed that bed net use and knowledge of malaria 
were associated with a lower prevalence in Lastourville. 
These results are consistent with previous data from 
Franceville, where bed nets were found to contribute to 
malaria prevention (JBL-D, pers. comm.).
Data revealed no link between preventive measures 
and malaria prevalence in Fougamou, Koula-Moutou or 
Franceville, possibly because bed net use was very high 
overall. Environmental conditions could also contribute to 
maintaining a high level of malaria transmission observed 
in the study sites, as previously reported in Nigeria [33]. 
Lastourville, Fougamou, Koula-Moutou, and Franceville 
are crossed by rivers that favour Anopheles breeding and 
proliferation. Children over 5  years old were most likely 
to contract malaria in urban areas, in keeping with results 
from Oyem (a semi-urban area in northern Gabon), Melen 
(a suburb of Libreville) and Port-Gentil [34]. Surprisingly, 
no effect of malaria on the haemoglobin level was found, 
except at Koula-Moutou. In contrast, malaria was associ-
ated with significantly lower WBC and platelet counts.
It was found that ACT implementation has led to an 
increase in the prevalence of P. falciparum genotypes 
N86, 184F and D1246 in both rural and urban areas of 
Gabon. This is consistent with previous data from Gabon 
showing a significant increase in the prevalence of wild-
type N86 at Oyem and Franceville [6, 9–11, 25, 26, 35]. 
Other studies in several African regions have shown sim-
ilar genotype selection [7, 10–12]. Datas indicate a risk of 
diminished P. falciparum sensitivity to AL, as reported 
in Tanzania where the wild-type N86 and 184F Pfmdr1 
genotypes were associated with an increased risk of AL 
treatment failure [10, 13]. These genotypes were also 
selected on re-infection after AL treatment [11]. The high 
prevalence of SNPs associated with decreased sensitivity 
to ACT observed here suggests that these latter drugs are 
widely used in Gabon. One reason of increased preva-
lence of N86 and D1246 may be that SNPs associated 
with AQ resistance (Y86 and Y1246) have a higher fit-
ness for parasites than N86 and D1246 [36], which would 
affect the selection pattern under different drug pressure. 
Another reason for change in prevalence of genotypes 
associated with CQ resistance could be the complete 
withdrawal of this drug as reported in Malawi [37]. Data 
founded show that NFD and YFD were the most preva-
lent haplotypes at each of the four study sites. NYD and 
YYD were the least prevalent and NFY, NYY, YYY, and 
YFY were not found at any of the sites (Table 3).
The findings are in keeping with those of a study from 
Maputo, where significant selection of NFD and NYD 
was observed 5–7  years after implementation of ACT 
in Mozambique [38]. In a study conducted in Tanzania, 
haplotype analysis showed a trend towards decreased 
lumefantrine susceptibility, in the order of NFD, NYD, 
YYY, and YYD [8]. This suggests gradual acquisition of 
tolerance, starting with N86, followed by the combina-
tion of N86 + D1246 and, thereafter, the combination of 
N86 + 184F + D1246 [8]. In Nigeria, the Pfmdr1 haplo-
type of NFD was selected in recrudescence samples after 
AL treatment, suggesting that this haplotype conferred a 
fitness advantage in case of AL pressure [17]. Other stud-
ies of African samples support the selection of the NFD 
haplotype by AL [11, 39], while YYY is selected by AQ 
or CQ [10, 11, 40–42]. The study confirms the effective 
withdrawal of monotherapy. It has been shown that para-
sites carrying the pfmdr1 NFD haplotype after AL treat-
ment are able to re-infect patients with lumefantrine 
blood concentrations 15-fold higher than for parasites 
carrying the YYY haplotype [8]. This could explain the 
selection of NFD in Gabon. The high prevalence of NYD 
found here is consistent with reports of the selection of 
this haplotype in other regions after the introduction of 
AL [38, 43]. Data from Zanzibar showed that NYD was 
selected after AS-AQ implementation [36].
Selection of Pfcrt K76 was reported after the imple-
mentation of ACT [44]. In the present work, the preva-
lence of wild-type K76 was higher than previously 
reported in Lambarene and Franceville, showing the 
increase in this genotype after long-term use of ACT [26, 
45]. This confirms that the increase in the prevalence of 
K76 after implementation of ACT occurs more slowly 
than the increase in N86 [6, 11]. Despite the significant 
increase in K76, its prevalence remains low. This could 
be explained by the late implementation of ACT in rural 
areas, even though ACT was already available in Gabon.
Mutations associated with artemisinin resistance in the 
K13 propeller gene (PF3D7_1343700 or PF13_0238) were 
not investigate in the study. Previous studies of samples 
from Gabon and other sub-Saharan African countries 
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did not show the presence of mutations (C580Y, R539T, 
Y493H) incriminated in in vivo artemisinin resistance in 
Southeast Asia [46].
Conclusion
This study shows an increase of the prevalence of plas-
modial infection in Gabonese children, according to low 
socio-economic level. An age inversion of the popula-
tion at risk in urban areas was found. A increase in the 
frequency of Pfmdr1 haplotypes NFD, YFD and NYD in 
both rural and urban areas was observed. Also, a grad-
ual increase in the frequency of the Pfcrt wild-type allele 
K76 in Franceville, 10  years after introduction of ACT 
in Gabon. Consequently, there is an urgent need to re-
inforce strategies against malaria in both urban and rural 
settings, and to monitor ACT.
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